Comparison between Avience Biomedicals IPO and Dasra Healthcare IPO.
Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Dasra Healthcare IPO is a SME Bookbuilding proposed to list at NSE SME.
| Avience Biomedicals IPO | Dasra Healthcare IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. | Mark Corporate Advisors Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Asnani Stock Broker Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | ||
| Final Prospectus | ||
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of Avience Biomedicals IPO is up to ₹0.00 Cr whereas the issue size of the Dasra Healthcare IPO is up to ₹0.00 Cr. The final issue price of Avience Biomedicals IPO is and of Dasra Healthcare IPO is .
| Avience Biomedicals IPO | Dasra Healthcare IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 15,27,600 shares | 37,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 15,27,600 shares | 37,50,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Avience Biomedicals IPO opens on , while Dasra Healthcare IPO opens on . The closing date of Avience Biomedicals IPO and Dasra Healthcare IPO is , and , respectively.
Avience Biomedicals IPO P/E ratio is , as compared to Dasra Healthcare IPO P/E ratio of .
| Avience Biomedicals IPO | Dasra Healthcare IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Avience Biomedicals Ltd.'s revenue increased by 89% and profit after tax (PAT) rose by 239% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.85 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.14 | 7.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.97 | 1.42 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 50.14 | 30.79 | |||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 0 shares while in Dasra Healthcare IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Avience Biomedicals IPO and in Dasra Healthcare IPO.
| Avience Biomedicals IPO | Dasra Healthcare IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 80,400 shares | |
| QIB | 0 shares | |
| NII | 0 shares | |
| RII | 0 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 0 shares |
Avience Biomedicals IPO subscribed in total, whereas Dasra Healthcare IPO subscribed .
